Editorial

DOI: 10.4244/EIJ-E-23-00052

Comparative preclinical assessment of drug-coated balloons: a blessing and a curse for clinical translation

Michael Joner1,2, MD; Léa Wild1,2, Med. Vet.

Drug-coated balloons (DCB) represent an established technology aimed at combining the dilatation of obstructive atherosclerotic vascular lesions with the rapid transfer of an antiproliferative drug to avoid neointimal hyperplasia. In contrast to standard drug-eluting stent (DES) technology, DCBs are targeted to provide antirestenotic efficacy in the absence of a persisting vascular prosthesis, consequently avoiding chronic vascular irritation and resultant inflammation. With the mainstream introduction of DCBs in 2006, Bruno Scheller and colleagues were able to demonstrate their antirestenotic efficacy in the clinical setting of coronary in-stent restenosis relative to plain old balloon angioplasty (POBA) in a randomised controlled trial1. Subsequently, a wealth of studies resulted in European guidelines recommending their primary use in this specific clinical setting2. Even today, clinical adoption of their broader application in other coronary lesion-specific settings, such as de novo lesions, bifurcations and small vessel disease, is slow despite the existence of dedicated studies to support their use. In addition, reports about the biological consequences of downstream particulate shedding during the deployment of paclitaxel-coated balloons (PCB) instigated a careful review of the existing literature,...

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 20 Number 6
Mar 18, 2024
Volume 20 Number 6
View full issue


Key metrics

Suggested by Cory

May 17, 2011
From bench to Paccocath
Cremers B and Scheller B
free
Trending articles
151.43

State-of-the-Art

10.4244/EIJ-D-22-00776 Apr 3, 2023
Computed tomographic angiography in coronary artery disease
Serruys PW et al
free
55.9

Clinical research

10.4244/EIJ-D-22-00621 Feb 20, 2023
Long-term changes in coronary physiology after aortic valve replacement
Sabbah M et al
free
54.9

Expert review

10.4244/EIJ-D-21-01010 Jun 24, 2022
Device-related thrombus following left atrial appendage occlusion
Simard T et al
free
43.75

Clinical Research

10.4244/EIJ-D-21-01091 Aug 5, 2022
Lifetime management of patients with symptomatic severe aortic stenosis: a computed tomography simulation study
Medranda G et al
free
39.95

Clinical research

10.4244/EIJ-D-22-00558 Feb 6, 2023
Permanent pacemaker implantation and left bundle branch block with self-expanding valves – a SCOPE 2 subanalysis
Pellegrini C et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved